There has been no report about in vivo active cholesterol-lowering dipeptide in any protein origin, despite their potential health benefits. Cattle heart protein hydrolysate ultra-filtrate (HPHU, molecular weight < ca. 1,000 Da peptide mixture) exhibits cholesterol-lowering activity in hypercholesterolemic rats, but the active peptide in HPHU that lowers serum cholesterol levels and its molecular mechanism are unknown. In this study, we separated and purified HPHU to identify a novel cholesterol-lowering dipeptide (phenylalanine-proline, FP) and characterized the mechanism underlying its effects in vivo and in vitro. We identified FP as an active peptide from HPHU by MALDI-TOF mass spectrometry. FP significantly decreased serum total and non-HDL cholesterol and hepatic cholesterol levels in rats. FP significantly increased serum HDL cholesterol, accompanied by a significant decrease in the atherogenic index. FP also significantly increased fecal cholesterol and acidic steroid excretion. Moreover, FP significantly decreased ATP-binding cassette transporter A1 (ABCA1) expression in the rat jejunum and reduced cholesterol absorption in Caco-2 cells. We found a novel cholesterol-lowering dipeptide FP that could improve cholesterol metabolism via the down-regulation of intestinal ABCA1. The cholesterollowering action induced by FP was disappeared in PepT1KO mice. FP-induced cholesterol-lowering action is mediated via PepT1 in mice.
Increased serum total cholesterol and LDL cholesterol and decreased HDL cholesterol induces hypercholesterolemia, which is a critical risk factor for atherosclerosis and ischemic heart disease 1, 2 . Therefore, the maintenance of proper cholesterol levels in the serum is essential for good health. The primary strategy for the prevention of disorders associated with hypercholesterolemia is dietary modification, including foods or dietary components with functional properties. Many researches using experimental animals and humans have suggested that vegetable proteins, such as soybean protein, can significantly decrease the risk of atherosclerosis by reducing plasma lipids [3] [4] [5] . Furthermore, recent studies have confirmed that various animal proteins, such as milk whey 6, 7 and egg white protein 8, 9 , have hypocholesterolemic effects. It has been reported that peptides or protein hydrolysates show greater bioactivity than that of intact proteins. Bioactive peptides have been produced in vitro by the chemical or enzymatic hydrolysis of several dietary proteins to modify and improve the physiological functions 7 . However, few studies have examined the effects of animal proteins and animal protein hydrolysates on cholesterol metabolism.
Cholesterol is a water-insoluble molecule; its intestinal absorption is complex, similar to other lipids, including a micellar solubilization step 10 . The modulation of intestinal cholesterol absorption by dietary protein and other food constituents may explain the cholesterol-lowering effects of foods. Some studies have suggested that dietary proteins, such as soybean protein 11, 12 and sunflower protein hydrolysates 13 decrease the micellar solubility of cholesterol in vitro and have hypocholesterolemic actions in animals. Very little is known about specific food-derived peptides that reduce serum cholesterol levels in vivo and hence more researches are required in this field.
We previously reported that cattle heart protein hydrolysate (HPH) and cattle heart protein hydrolysate ultra-filtrate (HPHU, MW < ca. 1,000 Da peptide fraction) exert strong hypocholesterolemic activity in rats 14 . HPH significantly reduces the serum total cholesterol and atherogenic index. HPH also significantly increases the fecal output of total steroids and cholesterol. The reduction of cholesterol uptake into Caco-2 cells was significantly greater in cholesterol micelles containing HPH than in the cholesterol micelles containing casein. The micellar solubility of cholesterol was significantly lower in the presence of HPH than in the presence of casein. Moreover, HPHU derived from HPH had a higher ability to reduce both serum and liver cholesterol concentrations than HPH in rats. We speculate that HPHU contains an active cholesterol-lowering peptide and a specific active peptide must play a pivotal role in the cholesterol-lowering actions of HPHU. However, the active peptide in HPHU and the mechanism underlying its cholesterol-lowering effect is unknown.
As about 80% of digested proteins are absorbed in the form of dipeptides or tripeptides, Proton-coupled oligopeptide transporter 1 (PepT1, Slc15A1) has an essential function in protein assimilation 15 . PepT1 is a highly conserved transporter that is existed in various mammalian species. PepT1mediates the uptake of di-and tripeptides in the intestine and kidney. PepT1 KO mice had generated to further clarify the physiological significance of existence of specific peptide transporters in the intestine 15 . PepT1 deletion drastically decreased the intestinal uptake of dipeptide GlySar, and its oral absorption by gastric intubation. There has been no report about the relationship between PepT1 and cholesterol-lowering action induced by dietary peptides and proteins. With the use of wildtype (WT) and PepT1 knockout (KO) mice, this study provided definitive evidence for the FP induced cholesterol-lowering action.
In this study, we separated and purified HPHU by size exclusion chromatography (SEC) and reversed-phase chromatography (RPC) to identify a novel cholesterol-lowering peptide. After the identification of an active peptide, we evaluated the mechanism underlying its cholesterol-lowering action in vivo including PepT1KO mice and in vitro.
Results
Purification of the inhibitory peptide for cholesterol micellar solubility in vitro. The typical elution profile of HPHU by a HiLoad 26/60 Superdex 30 pg column is shown in Fig. 1A . Peaks (1−4) were consistently detected in separate experiments. The fractions gf1-gf4 were collected and the effect of these fractions on cholesterol micellar solubility in vitro were evaluated as shown in Fig. 1B . The fractions gf1, gf2, gf3, and gf4 accounted for approximately 23.6%, 17.4%, 14.8%, and 1.4% of HPHU, respectively. The cholesterol micellar solubility of HPHU (79.1%) or gf3 (79.9%) was significantly lower than those of CTH (control) or other fractions, like gf1 (95.6%), gf2 (96.2%), or gf4 (98.0%), as shown in Fig. 1B . These results suggested that active peptides of HPHU related to the inhibitory effect on cholesterol micellar solubility are concentrated in the gf3 fraction.
The typical RPC elution profile of gf3 is shown in Fig. 1C . The gf3 fraction was separated into RPI (0% B), RPII (0-10% B), RPIII (10-20% B), and RPIV (20-30% B) and the effect of these fractions on the micellar solubility of cholesterol was evaluated in vitro. The fractions RPI, RPII, RPIII, and RPIV accounted for approximately 65.0%, 14.5%, 3.0%, or 0.75% of gf3, respectively. RPI (70.1%), RPII (70.6%), and RPIII (67.8%) showed lower cholesterol micellar solubilities than RPIV (87.2%), as shown in Fig. 1D .
The typical RPC elution profile of RPI is shown in Fig. 1E . RPI was separated into six fractions, IA-IF, and the effects of the fractions on the micellar solubility of cholesterol were evaluated in vitro. The fractions IA, IB, IC, ID, IE, or IF accounted for approximately 39.0%, 12.7%, 4.0%, 6.7%, 4.1%, and 2.4% of RPI, respectively. IA (72.3%) and IB (66.8%) showed lower cholesterol micellar solubilities than IC (86.7%), ID (75.2%), IE (82.4%), and IF (94.5%), as shown in Fig. 1F .
The typical RPC elution profile of IB is shown in Fig. 1G . IB was separated into four fractions, IB1-IB3, and the effects of the fractions on the micellar solubility of cholesterol were evaluated in vitro. The fractions IB1, IB2, and IB3 accounted for approximately 12.8%, 13.4%, or 10.5% of the IB fraction, respectively. IB2 (46.6%) showed lower cholesterol micellar solubility than IB1 (78.9%) or IB3 (88.1%), as shown in Fig. 1H .
Molecular weight distribution of IB2 containing peptides estimated by gel filtration. IB2
contained the peptides having a molecular weight < 700 was estimated by gel filtration using Superdex Peptide 10/300 GL ( Fig. 2A ). Peptide molecular weight 700~200 or 200~75 was contained in IB2 fraction 33% or 67% respectively by calculating the area of elution profile as shown in Fig. 2B .
Identification of an active peptide (FP) in IB2.
The MALDI-TOF/MS spectrum revealed that IB2 contained some peptides, including FP (261.18 m/z) as shown in Fig. 3A . FP was identified by MS/MS analysis ( Fig. 3B ). FP can be released from Myosin-2 or Actin (alpha-cardiac muscle), the major cattle heart protein, and their position within Myosin-2 (Q9BE41) from N to C terminal: 78-79, 543-544, 714-715 or Actin (Q3ZC07) from 43-44 in data bases.
Effect of CTH, HPHU or FP on cholesterol micellar solubility in vitro and cholesterol absorption
in Caco-2 cells. Micellar solubility of cholesterol in vitro was significantly decreased by HPHU or FP compared with CTH ( Fig. 4A ) To address whether HPHU or FP can inhibit cholesterol absorption, Caco-2 cells were treated with micelle containing FP, HPHU or CTH. Cholesterol uptake from the micelle with FP or HPHU (5 g/L) was significantly lower than that from the micelle containing CTH (Fig. 4B ).
investigate the effect of FP on the mRNA levels of cholesterol metabolism-related genes in Caco-2 cells, we performed real-time PCR using Caco-2 cells treated with or without 1 mM FP for 24 h. We investigated whether FP affected the mRNA levels of ABCA1, Niemann-pick C1-like 1 L1 (NPC1L1), Acyl-coenzyme A: cholesterol acyltransferase 2 (ACAT2), Microsomal triglyceride transfer protein (MTP), Apolipoprotein AI (ApoAI), Sterol regulatory element binding protein 2 (SREBP2), Liver X receptor α (LXRα), and Liver X receptor β (LXRβ). The addition of FP significantly decreased the mRNA levels of ABCA1 and NPC1L1 ( Fig. 5A ). Recent studies have shown that SREBP and LXR are important transcription factors that regulate ABCA1 and NPC1L1 gene transcription. FP significantly decreased the LXRβ mRNA level (Fig. 5A ). In addition, SREBP2 and LXRα mRNA levels tended to be lower in FP-treated group than in the control group (Fig. 5A ).
Effect of FP on ABCA1, NPC1L1, and LXR protein levels in Caco-2 cells. To evaluate the relation-
ships between mRNA and protein levels, we further evaluated the protein levels of ABCA1, NPC1L1, LXRα, and LXRβ in Caco-2 cells. FP significantly decreased the ABCA1 protein level ( Fig. 5B,C) . However, FP did not affect NPC1L1, LXRα, and LXRβ levels ( Fig. 5B,C) . www.nature.com/scientificreports www.nature.com/scientificreports/ Effect of FP on ABCA1 promoter activity in Caco-2 cells. We investigated the effect of FP on ABCA1 gene promoter activity. Caco-2 cells were treated with or without 1 mM FP for 12 h, and the cell lysates were subjected to a luciferase assay. FP did not significantly affect ABCA1 promoter activity ( Fig. 5D ).
Effect of FP on metabolic parameters in rats fed a high-fat high-cholesterol diet. The body
weight gain, total food intake, and liver weight were unaffected by dietary treatment over 14 days ( Fig. 6A -G). The serum total and non-HDL-cholesterol concentrations in the HFCFP (High Fat and High Cholesterol diet fed FP: FP group) group were significantly lower than those in the HFC (High Fat and High Cholesterol diet without FP: Control group) group. The serum HDL cholesterol level was significantly higher in the HFCFP group than in the HFC group, resulting in a significant decrease in the atherosclerosis index. The serum triglyceride level tended to be lower in the HFCFP group than in the HFC group. Liver cholesterol and liver total lipids in the HFCFP group were significantly lower than those in the HFC group. The levels of fecal steroid excretion of acidic steroids and cholesterol in the HFCFP group were significantly higher than those in the HFC group.
Effect of FP on the mRNA levels of cholesterol metabolism-related genes in rats.
We evaluated the effect of FP on the mRNA levels of cholesterol metabolism-related genes in rats. FP did not significantly affect the hepatic mRNA expression of genes related to cholesterol metabolism such as low density lipoprotein receptor (LDLR), cholesterol 7α-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), SREBP2 or ApoAI, but tended to increase ABCA1 mRNA expression related to HDL formation (P = 0.088, 150%) ( Fig. 6H ). In contrast, FP induced a decrease in the ABCA1 mRNA level in the jejunum related to the inhibitory action of intestinal cholesterol absorption ( Fig. 6I ).
Effect of FP on metabolic parameters and cholesterol absorption in
PepT1 knockout (KO) and wildtype (WT) mice fed a high-fat high-cholesterol diet. The body weight gain was significantly increased in WTFP group compared to WTC group, and KOFP group compared to KOC group. Food intake was significantly increased in KOFP group compared to KOC group. Liver weight was significantly decreased in WTFP compered to WTC group (Supplementary Table 1 ). Serum cholesterol in WTFP group was significantly lower than that in WTC group (Fig. 7A ). Liver cholesterol (Fig. 7B ) and liver total lipids (Supplementary Table 1 ) www.nature.com/scientificreports www.nature.com/scientificreports/ in WTFP group were significantly lower than those in the WTC group and were not significantly changed among KO groups. Cholesterol absorption was significantly decreased in WTFP compared to WTC and was not significantly changed among KO groups (Fig. 7C ).
Discussion
FP is the world's first cholesterol-lowering dipeptide. This is the first study to identify FP as a novel cholesterol-lowering dipeptide. We previously reported that HPHU exhibits a cholesterol-lowering effect in vivo and in vitro 14 . However, the active peptide of HPHU and the mechanisms by which the active peptide induces a hypocholesterolemic effect were unknown. In the present study, in addition to identifying FP, we evaluated its cholesterol-lowering action in vivo and in vitro.
In particular, we evaluated the inhibitory effect of HPHU fractions on cholesterol micellar solubility and identified the peptide sequences. Several studies have suggested that suppressed cholesterol micellar solubility is related to the inhibitory action of cholesterol absorption in Caco-2 cells and in vivo. It is well known that the human epithelial cell line Caco-2 has been widely used as a model of the intestinal epithelial cells 16 . For example, HPHU, soy protein peptic hydrolysate (SPH), and β-lactoglobulin tryptic hydrolysate (LTH) have inhibitory effects on both cholesterol micellar solubility and cholesterol absorption in Caco-2 cells and are associated with a negative correlation between serum total cholesterol and fecal total steroid excretion in vivo 7, 11, 14, 17, 18 . Therefore, we speculated that the active peptides in HPHU had inhibitory effects on cholesterol micellar solubility and cholesterol absorption in Caco-2 cells, accompanied by a negative correlation between serum total cholesterol and fecal total steroid excretion. Thus, we identified an active dipeptide, FP by evaluations of cholesterol micellar solubility and cholesterol absorption in Caco-2 cells in vitro. However, FP-containing fraction is not the only one carrying cholesterol-lowering properties (Fig. 1) . Moreover, FP peptide may not be the only peptide in the fraction that has hypocholesterolemic properties ( Fig. 3 ). We will be going to clarify the active peptide other than FP to evaluate whether the cholesterol-lowering action of HPHU is due to FP peptide or other peptides. Also, we need to clarify the contribution of FP on the cholesterol-lowering action of HPHU by preparing FP-free HPHU in future study. Moreover, we demonstrated that orally administrated FP results in significant reductions in serum total and non-HDL-cholesterol concentrations in hypercholesterolemic rats fed a high-fat high-cholesterol diet (Fig. 7E) . This result suggests that FP, a cholesterol-lowering peptide, is directly responsible for the hypocholesterolemic effects of HPHU. In the present study, the high level of serum HDL cholesterol in response to FP treatment indicate that FP results in a significant decrease in the atherogenic index (total cholesterol/HDL-cholesterol), which may result in the transfer of peripheral free cholesterol to the liver by a mechanism known as "reverse cholesterol transfer, " promoted by HDL cholesterol.
The blood cholesterol level is determined by cholesterol absorption, synthesis, storage, degradation, and excretion 19 . In our previous study, we found a significant correlation between fecal total steroids excretion and serum total cholesterol in rats 11 . Thus, our data suggested that the fecal excretion of bile acids and cholesterol could be affected by FP feeding. FP induced a significant increase in the fecal excretion of bile acids and cholesterol compared to levels in the control. Thus, the cholesterol-lowering action of FP inhibited intestinal cholesterol absorption and stimulated fecal steroid excretion.
Furthermore, to investigate the mechanism by which FP treatment decreased serum total and non-HDL-cholesterol concentrations in rats, we evaluated the effects of FP on cholesterol metabolism-related genes in rats and Caco-2 cells as a model of the small intestine. FP did not significantly affect hepatic mRNA expression of genes related to cholesterol metabolism, but tended to increase hepatic ABCA1 mRNA expression in rats (Fig. 6H) . FP resulted in a significant decrease in ABCA1 mRNA levels in the jejunum (Fig. 6I ). Furthermore, we clarified that FP induced a significant decrease in the ABCA1 mRNA level accompanied by a down-regulation of ABCA1 protein levels in Caco-2 cells (Fig. 5) . These results related to Caco-2 cells are consistent with the results of in vivo rat experiments about jejunal ABCA1. FP did not affect cell growth measured by WST-1 method up to 1 mM in Caco-2 cells. We need to measure how much FP is detected in the stomach and gut content following HPHU supplementation in rats to optimize the effects of FP on cholesterol metabolism in Caco-2 cells in future study.
In addition, we found that cholesterol absorption decreased significantly in response to FP treatment in Caco-2 cells (Fig. 4B ). NPC1L1 has a critical role in the intestinal absorption of dietary cholesterol, and the inhibition of NPC1L1 expression has a protective effect against hypercholesterolemia 20, 21 . Our results showed that FP induced a significant decrease in NPC1L1 mRNA expression did not significantly affect NPC1L1 expression at the protein level ( Fig. 5 ). Therefore, we speculate that the effect of FP on cholesterol absorption does not involve NPC1L1 expression.
ABCA1 mediates HDL cholesterol biogenesis by promoting the efflux of cholesterol and phospholipids to ApoAI 22 . ABCA1 is widely expressed throughout the body. However, studies have shown that hepatic and intestinal ABCA1 explain ~30% of plasma HDL cholesterol levels 22 . Recent studies have shown that cholesterol absorption in intestinal ABCA1 KO mice is reduced by ~28% and total plasma cholesterol is reduced by approximately 30% 23 . It is possible that the effect of FP on cholesterol absorption involves the down-regulation of ABCA1 expression. Though a truly useful intestinal ABCA1 specific inhibitor to decrease blood cholesterol has not yet to be discovered, peptides should be a key molecule to finding one. The expression of ABCA1 is regulated by ABCA1 gene transcription and mRNA stability. ABCA1 gene transcription is mainly regulated by liver X receptors (LXRs). Excess cholesterol accumulation induces ABCA1 expression via LXRs 24, 25 . We found that FP induces a significant decrease in the LXRβ mRNA level but did not affect LXRβ protein levels in Caco-2 cells (Fig. 5 ). Furthermore, we found that the down-regulation of ABCA1 mRNA was not caused by a decrease in ABCA1 transcriptional activity (Fig. 6 ). Thus, we speculate that the down-regulation of ABCA1 may be related to a decrease in mRNA stability by FP. We need to clarify the detailed mechanism about ABCA1 downregulation induced by FP in rats in future study. Recent studies have clarified that ABCA1 mRNA stability is regulated by micro-RNAs and RNA binding proteins [26] [27] [28] [29] [30] [31] . In future studies, it is necessary to evaluate the effects of FP on miRNA and RNA binding protein profiles.
While, apoE mimetic peptides have increased potency to reduce plasma cholesterol through the changes of electrophoretic mobility of LDL particle in mice 32 . We tried to experimentally evaluate the effect of FP on the electrophoretic mobility of LDL particle in vitro. Our results suggested that FP did not affect the electrophoretic mobility of LDL particle in vitro. Thus, we suggest that the mechanism of cholesterol-lowering action of FP is different from apoE mimetic peptides.
We had already discovered an in vivo active novel cholesterol-lowering pentapeptide, IIAEK (lactostatin) mediated the novel Ca-channel related Mitogen Activated Protein Kinase (MAPK) pathway for cholesterol degradation in human hepatocytes 33, 34 . We speculate that lactostatin induce cholesterol degradation mediated a novel pathway via a hypothetical membrane lactostatin receptor (receptor hypothesis) and dipeptides, such as EK, mediate a novel pathway via a non-membrane receptor (the proton-coupled oligopeptide transporter 1 (PepT1) mediated pathway (non-receptor hypothesis) 34, 35 . As FP can enter into Caco-2 cells through PepT1, we speculate that FP may mediate a novel pathway via a non-membrane receptor in the intestinal cell. Interestingly, FP-induced the cholesterol-lowering action was disappeared in PepT1KO mice. Thus, this shows that FP-induced cholesterol-lowering action is mediated via PepT1 in mice ( Fig. 8 ) This clearly suggests that PepT1 is a crucial target for the improvement of cholesterol metabolism.
While, soybean glycinin derived three kinds of peptides (IAVPGEVA, IAVPTGVA, and LPYP) that are able to activate the low-density lipoprotein (LDL) receptor−SREBP2 pathway in HepG2 cells in vitro 36 . Thus, we need to clarify the molecular action of in vivo active cholesterol-lowering oligopeptides including IIAEK mediated via a membrane receptor or a non-membrane receptor in the future.
In summary, we identified the novel hypocholesterolemic dipeptide FP from HPHU by MALDI-TOF mass spectrometry as well as in vitro and in vivo assays related to cholesterol metabolism. Hypocholesterolemic dipeptides derived from proteins have not been characterized. FP significantly reduced serum total cholesterol, non-HDL-cholesterol, and hepatic cholesterol concentrations in hypercholesterolemic rats. FP significantly increased serum HDL cholesterol, resulting in a significant decrease in the atherogenic index. FP also significantly increased the fecal excretion of acidic steroids and cholesterol. Our results show that FP reduces intestinal cholesterol absorption via the down-regulation of ABCA1 expression. There is no scientific principle about the relationship between the structure (including amino acid sequence) and activity of cholesterol-lowering action. We need to clarify this unknown principle to find new peptides and promote the development of new functional foods and atherogenic drugs. Thus, these novel findings about FP play a crucial role in both the study of the effect of peptides on cholesterol metabolism and new functional foods and atherogenic drugs.
Methods

Preparation of the cattle heart protein hydrolysate ultra-filtrate (HPHU). HPHU was provided by
Itoham Foods Inc. (Ibaraki, Japan). Samples were prepared as described in our previous study 14 . HPHU consisted of 81.3% protein, 3.5% sugar, 0.4% lipids, 7.7% ash, and 7.1% moisture.
Purification of the inhibitory peptide for cholesterol absorption or cholesterol micellar solubility in vitro. HPHU was separated according to the procedure described previously with some modifications.
SEC was performed using a HiLoad 26/60 Superdex 30 pg Column (GE Healthcare) and the AKTA Avant 25 www.nature.com/scientificreports www.nature.com/scientificreports/ system (GE Healthcare). HPHU (0.57 g) was dissolved in 10 mL of deionized water and applied to the column. The flow rate was 2.0 mL/min. Online UV absorbance was monitored at 215 nm. The typical elution profile was shown in Fig. 1A . The eluted fractions (gf1~gf3) were collected and the effect on cholesterol micellar solubility was evaluated in vitro.
The fraction with the greatest inhibitory effect on cholesterol micellar solubility was collected (gf3), lyophilized, and further fractionated by RPC using a column (SOURCE 5RPC ST 4.6/150; GE Healthcare). The conditions for RPC were as follows. Solvent A was 0.065% trifluoroacetic acid (TFA) in 2% acetonitrile and solvent B was 0.05% TFA in 80% acetonitrile. The flow rate was 1 mL/min. The solvent gradient was initially 0% B for 35 min, then changed from 0% to 10% B for 35 min, from 10% to 20% B for 35 min, from 20% to 30% B for 35 min, and from 30% to 100% B for 47.5 min. Online UV absorbance was monitored at 215 nm. The typical elution profile was shown in Fig. 1C . The fractions (RPI~RPIV) were collected and the effect of these fractions on cholesterol micellar solubility was evaluated in vitro.
The fraction (RPI) with the greatest inhibitory effect on cholesterol micellar solubility was collected, lyophilized, and further fractionated by RPC using the same column described above. The conditions for RPC were as follows. Solvent A was 0.065% TFA in 2% acetonitrile and solvent B was 0.05% TFA in 80% acetonitrile. The solvent gradient was initially 0% B for 2.5 min, then changed from 0% to 11% B for 55 min and from 11% to 100% B over 10 min. Online UV absorbance was monitored at 215 nm. The typical elution profile was shown in Fig. 1E . The fractions (IA~IF) were collected and the effect of these fractions on cholesterol micellar solubility was evaluated in vitro.
The fraction (IB) with the greatest inhibitory effect on cholesterol micellar solubility was collected, lyophilized, and further fractionated by RPC using the same column described above. The conditions for RPC were as follows. Solvent A was 0.065% TFA in 2% acetonitrile and solvent B was 0.05% TFA in 80% acetonitrile. The solvent gradient was initially 0% B for 2.5 min, then changed from 0% to 4% B for 25 min and from 11% to 100% B over 12.5 min. Online UV absorbance was monitored at 215 nm. The typical elution profile was shown in Fig. 1G . The fractions (IB1~IB3) were collected and the effect of these fractions on cholesterol micellar solubility was evaluated in vitro.
Effects of fractions derived from HPHU, CTH or FP on cholesterol micellar solubility in vitro.
The effects of HPHU fractions, CTH or FP on cholesterol micellar solubility were evaluated in vitro using a previously described method 11, 37 . The [4-14 C]-labeled micellar solutions (1.0 mL) containing the following components were mixed by sonication (Ultrasonic Homogenizer, Model VP-5; Taitec, Tokyo, Japan): 0.74 kBq [4-14 C]-cholesterol (2.1 Gbq/mmol; PerkinElmer Life Sciences, Yokohama, Japan), 0.1 mM cholesterol (Sigma Aldrich, St. Louis, MO, USA), 6.6 mM sodium taurocholate (Sigma Aldrich), 1 mM oleic acid (Sigma Aldrich), 0.6 mM phosphatidylcholine (Sigma Aldrich), 0.5 mM monoolein (Sigma Aldrich), 132 mM NaCl, and 15 mM sodium phosphate buffer (pH 7.4). After incubation at 37 °C for 24 h, the sample (5 g/L, respectively) was added to the micellar solution, solubilized by sonication, incubated at 37 °C for 1 h, and centrifuged at 100,000 × g for 60 min at 37 °C. The supernatant was collected for the determination of the [ 14 C]-cholesterol content using a liquid scintillation counter.
Molecular weight (M.W.) distribution of IB2 containing peptides estimated by gel filtration. Molecular weight distribution of IB2 containing peptides estimated by gel filtration. IB2 contained the peptides having a molecular weight < 700 was estimated by gel filtration using Superdex Peptide 10/300 GL (GE Healthcare) and the AKTA Avant 25 system (GE Healthcare). Molecular marker is IIAEKK (M.W. 700.1), IIAE (M.W. 445.3), IIA (M.W. 316.2), IA (M.W. 201), G (M.W. 75). IB2 (0.5 mg) was dissolved in 1 mL of 150 mM NaCl, 0.02 M phosphate buffer (pH 7.5) and applied to the column. The flow rate was 2.0 mL/min. Online UV absorbance was monitored at 220 nm.
MALDI-TOF/MS analyses.
The peptide in the fraction IB2 was analyzed by MALDI-TOF mass spectrometry (AXIMA Performance, SHIMADZU).
Chemicals. FP (Phenylalanine-proline: purity (>95%)) was obtained from Bachem AG (Bubendorf, Switzerland).
Cholesterol absorption assay for Caco-2 cells. Caco-2 cells were grown in 48-well plastic dishes containing 0.5 mL of fetal bovine serum supplemented with DMEM for 14 days post-confluence. [ 14 C]-Labeled micellar cholesterol uptake in Caco-2 cells for 120 min was measured as described previously 11 . The [ 14 C]-labeled micellar solutions (0.5 mL) contained casein tryptic hydrolysate (CTH), HPHU or FP, 5 g/L respectively. The [4-14 C]-labeled micellar solution (6 mL) was prepared at the following concentrations and mixed by sonication (Taitec, VP-5): 3.7 kBq [4-14 C]-cholesterol (2.0 Gbq/mmol, NEN), 2 µmol/L cholesterol (Sigma Aldrich), 6.6 mmol/L sodium taurocholate (Sigma Aldrich), 20 µmol/L oleic acid (Sigma Aldrich), 0.6 mmol/L phosphatidylcholine (Sigma Aldrich), 5 µmol/L monoolein (Sigma Aldrich). The cellular protein was determined using a commercially available kit (Bio-Rad Protein Assay; Bio-Rad).
Cell culture. Caco-2 cells were acquired from the American Type Culture Collection (Manassas, USA).
The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 4 mmol/L l-glutamine, 50,000 IU/L penicillin, and 50 mg/L streptomycin. For experiments, cells were seeded in 6-well Transwell ® plates (Corning, Inc., USA) at a density of 2 × 10 5 cells/well and grown for 14 days post-confluence. On day 14, the medium was replaced with serum-free DMEM with or without FP. All cells were incubated at 37 °C in a humidified atmosphere of 5% CO 2 in air.
